How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!

IKT Insider Trading (Inhibikase Therapeutics)

Insider Ownership Percentage: 55.80%
Insider Buying (Last 12 Months): $46,470.33
Insider Selling (Last 12 Months): $0.00

Inhibikase Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Inhibikase Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibikase Therapeutics Share Price & Price History

Current Price: $1.65
Price Change: Price Decrease of -0.12 (-6.78%)
As of 12/3/2021 01:00 AM ET

This chart shows the closing price history over time for IKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Which State Is Ranked #1 For Lithium Investors?
The Fraser Institute ran a survey to find the best spot in the world for lithium mining. They researched 77 spots from around the world… and the Nevada Desert won the #1 spot by a landslide. And this small mining company just staked 11,700 acres of mineral claims in Nevada's hottest lithium spot...
See Why This Lithium Stock Could Explode

Inhibikase Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Milton H WernerCEOBuy23,589$1.97$46,470.33View SEC Filing Icon  
See Full Table
Insider Selling at Inhibikase Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Inhibikase Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Inhibikase Therapeutics (NYSE:IKT)

20.97% of Inhibikase Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IKT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Inhibikase Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/18/2021Bank of New York Mellon Corp39,580$75K0.0%N/A0.157%Search for SEC Filing on Google Icon
11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103%Search for SEC Filing on Google Icon
11/16/2021Millennium Management LLC101,278$0.19M0.0%N/A0.403%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC25,833$49K0.0%N/A0.103%Search for SEC Filing on Google Icon
11/10/2021Goldman Sachs Group Inc.27,895$53K0.0%N/A0.111%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202%Search for SEC Filing on Google Icon
8/17/2021Zeke Capital Advisors LLC93,800$0.26M0.0%+398.9%0.926%Search for SEC Filing on Google Icon
8/16/2021Antara Capital LP250,000$0.70M0.0%N/A2.467%Search for SEC Filing on Google Icon
8/16/2021Warberg Asset Management LLC90,000$0.25M0.0%N/A0.888%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP109,749$0.31M0.1%N/A1.083%Search for SEC Filing on Google Icon
8/13/2021Murchinson Ltd.320,947$0.90M0.3%N/A3.167%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644%Search for SEC Filing on Google Icon
8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276%Search for SEC Filing on Google Icon
8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More on Inhibikase Therapeutics

Today's Range

Now: $1.65
Low: $1.54
High: $1.77

50 Day Range

MA: $1.94
Low: $1.65
High: $2.17

52 Week Range

Now: $1.65
Low: $1.54
High: $11.80

Volume

542,485 shs

Average Volume

360,914 shs

Market Capitalization

$41.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inhibikase Therapeutics?

Inhibikase Therapeutics' top insider investors include:
  1. Milton H Werner (CEO)

Who are the major institutional investors of Inhibikase Therapeutics?

Inhibikase Therapeutics' top institutional investors include:
  1. ACT Capital L.L.C. — 4.02%
  2. Millennium Management LLC — 0.40%
  3. BlackRock Inc. — 0.20%
  4. Bank of New York Mellon Corp — 0.16%
  5. Goldman Sachs Group Inc. — 0.11%
  6. Warberg Asset Management LLC — 0.10%

Which major investors are selling Inhibikase Therapeutics stock?

In the last quarter, IKT stock was sold by these institutional investors:
  1. Warberg Asset Management LLC

Which major investors are buying Inhibikase Therapeutics stock?

In the last quarter, IKT stock was bought by institutional investors including:
  1. ACT Capital L.L.C.
  2. Millennium Management LLC
  3. Bank of New York Mellon Corp
  4. BlackRock Inc.
  5. Goldman Sachs Group Inc.
  6. Geode Capital Management LLC
Washington State's Legal Cannabis Stock Enjoying Explosive Growth
Nearly a decade ago, two ambitious entrepreneurs in the Seattle area saw the potential behind Washington State's referendum to legalize recreational use of cannabis. They created a company that has seen sales grow 8X since inception. Now they're poised to expand nationwide.
Get All the Details in Brand-New Special Report!